established a Scientific Advisory Board (SAB) and has appointed
Adial Pharmaceuticals, Inc. today announced that it has established a Scientific Advisory Board (SAB) and has appointed Dr. Giovanni Addolorato, a leading global expert in the field of alcohol use disorder (AUD), as its first member and Chairperson. The SAB will help to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.
globenewswire.com/news-release/2018/11/29/1659033/0/en/Adial-Pharmaceuticals-Establishes-Scientific-Advisory-Board-and-Appoints-Global-Thought-Leader-in-the-Field-of-Alcohol-Use-Disorder.html
seekingalpha.com/news/3413224-adial-pharmaceuticals-tonix-pharmaceuticals-among-healthcare-gainers-restoration-robotics
globenewswire.com/news-release/2018/11/29/1659033/0/en/Adial-Pharmaceuticals-Establishes-Scientific-Advisory-Board-and-Appoints-Global-Thought-Leader-in-the-Field-of-Alcohol-Use-Disorder.html
seekingalpha.com/news/3413224-adial-pharmaceuticals-tonix-pharmaceuticals-among-healthcare-gainers-restoration-robotics
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.